Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for various diseases. Founded with the aim of harnessing the potential of peptides as targeted and effective treatments, the company primarily advances programs in gastrointestinal and inflammatory diseases, leveraging proprietary peptide delivery platforms.
Company News
Moody Aldrich Partners LLC completely sold its entire 35,228 share position in Chart Industries, valued at approximately $5.8 million, reducing its reportable assets to zero in Q3 2025.
Johnson & Johnson reported strong Q3 2025 earnings, beating consensus estimates, and announced plans to separate its Orthopedics business into a standalone entity called DePuy Synthes within 18-24 months, targeting increased top-line growth and operating margins.
BESREMi, a FDA-approved treatment for polycythemia vera, is gaining market share due to its potential for better tolerability and lower risk of treatment-related malignancies compared to competitors like ruxolitinib and hydroxyurea.
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.